

Pharma Bavaria Broadens Pipeline with New Product for treating Diabetic Foot Ulcers

Estoril, Portugal – 17th October 2024, 5:00 PM CET – Pharma Bavaria International Group, (Pharma Bavaria) announced today the signing of a multi-regional licensing agreement with Energenesis Biomedical for ENERGI-F703DFU. This product, currently undergoing Phase III clinical trials in the US and Taiwan, is designed for treating diabetic foot ulcers (DFU).

Under the agreement, Pharma Bavaria will be responsible for product registration, logistics, marketing and sales in Portugal and certain emerging markets in the Middle East with an option to extend to countries in Africa and certain Latin American markets.

Access to emerging markets require a significant investment of time and resources, and Pharma Bavaria's expertise in these areas is a critical factor in Energenesis Biomedical's growth strategy. The clinical validation of ENERGI-F703DFU for healing diabetic foot ulcers addresses a significant unmet need.

Gagan Datta, Chief Commercial Officer of PBI added:

"We are thrilled with the possibility of launching ENERGI-F703DFU a groundbreaking innovation designed to revolutionize the treatment of diabetic foot ulcers. With this cutting-edge solution, we expect to drastically advance the wound healing process, enhance patient comfort and significantly improve the quality of life for the patients. We are committed to commercialize the product under our tradename through our distributors in the various countries in different regions to ensure widespread access to this transformative product."

About diabetic foot ulcers (DFU)¹²³

The prevalence of diabetes mellitus (DM) is rapidly spreading at an alarming rate worldwide. DM is known to damage multiple organs, including the heart, kidney, eye, and nerves, leading to complications such as heart attack, stroke, blindness, kidney failure, and lower limb amputation. Diabetic foot ulcer (DFU) is a frequent complication that occurs in approximately 6.3% of patients with DM globally [1]. It may take weeks or even several months for foot ulcers to heal [2].

The high incidence of DFU and the associated mortality and morbidity are the most common reasons for hospitalization of DM patients.

Early during DM, patients experience serious foot sensitivity symptoms such as pain and tingling, while later stages of the disease course are characterized by negative symptoms such as numbness and weakness of the toes. With the progression of the disease, patients usually show mixed pain sensitivity and dullness, along with decreased limb sensation and motor function, which lead to imbalance and unsteadiness and increase the likelihood of falls. In addition, because of the increasing morbidity, DFU is a leading cause of non-traumatic amputation and is associated with an increased risk of death [1]. In Western countries, the annual incidence of foot ulceration in the diabetic population is around 2%. DFUs develop as a consequence of a combination of factors, most commonly peripheral neuropathy (loss of the gift of pain), peripheral arterial disease (PAD), and some form of unperceived trauma. All

¹ <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791567/>

² <https://medlineplus.gov/ency/patientinstructions/000077.htm>

³ <https://www.ncbi.nlm.nih.gov/books/NBK409609/>

patients with diabetes should have an annual screen to identify their foot ulcer risk status: those with any risk factors require specific foot care education as well as regular contact with a health care professional, usually a podiatrist. DFUs should heal if there is an adequate arterial inflow, infection is aggressively managed, and pressure is removed from the wound and its margins [3].

About Pharma Bavaria

Pharma Bavaria was founded in 2014 and is a pharmaceutical company that distributes and promotes pharmaceuticals in more than 45 countries.

Pharma Bavaria focus on growth regions such as the Middle East, Africa, South-East Asia, CIS, LATAM.

Its portfolio of prescription medicines covers cardiology, gastroenterology, woman’s health, anti-infective, analgesic/anti-inflammatory, oncology, urology, and other therapeutic areas.

For more information, visit <https://pharma-bavaria.com> and follow-us on [LinkedIn](#).

About Energenesis Biomedical

Energenesis Biomedical Co., Ltd. operates as a drug products development company and it was founded in 2012, in Taiwan and granted the qualification of biomedicine company by the Ministry of Economic Affairs in 2015. Energenesis Biomedical is company, aiming to make substantive contribution to the global biotech industry.

For more information, contact PBI:

Headquarters

Pharma Bavaria International GmbH
Postweg 4a
83209 Prien am Chiemsee
Germany

Phone
+49 (0) 8051 – 9619714

EU-Subsidiary

Pharma Bavaria International (PBI)
Portugal Unip, Lda.
Viela da Beloura, nº 6, loja 19
2710 – 693 Sintra

Office Address

Rua dos Ciprestes nº 48,
2765-623 Estoril

Phone
+351 214682905

UAE-Subsidiary

Pharma Bavaria International (PBI)
Pharma Bavaria International
c/o G D Management
Consultancy
Office no. 3004-D, 30th Floor,
AspinTowers
Sheikh Zayed Road. Dubai, UAE

Phone
+971 506591122